CD19 and neoplasm: Blinatumomab, a BiTE composed of a 55-kDa fusion protein that contains scFvs, linked by a glycine-serine linker, targets CD19 on tumor cells by the redirection of CD3 positive cytotoxic T cells to lyse CD19 positive tumor cells.